Skip to content


Experimental Hematology & Oncology


Sort by
Previous Page Page 1 of 9 Next Page
  1. Content type: Case report

    Acquired primary chromosomal changes in cancer are sometimes found as sole karyotypic abnormalities. They are specifically associated with particular types of neoplasia, essential in establishing the neoplasm,...

    Authors: Ioannis Panagopoulos, Ludmila Gorunova, Hege Kilen Andersen, Astrid Bergrem, Anders Dahm, Kristin Andersen, Francesca Micci and Sverre Heim

    Citation: Experimental Hematology & Oncology 2018 7:7

    Published on:

  2. Content type: Case report

    Immune checkpoint blockade (ICB) is becoming an increasingly prevalent strategy in the clinical realm of cancer therapeutics. With more patients being administered ICB for a host of tumor types, the scope of a...

    Authors: D. E. Meyers, W. F. Hill, A. Suo, V. Jimenez-Zepeda, T. Cheng and N. A. Nixon

    Citation: Experimental Hematology & Oncology 2018 7:6

    Published on:

  3. Content type: Rapid communication

    Expression of SRY [sex-determining region Y]-box11 (SOX11) is specific to mantle cell lymphoma (MCL) and contributes, in conjunction with immunoglobulin variable heavy chain gene mutation status, to the identi...

    Authors: Julien Magne, Alizée Jenvrin, Adrien Chauchet, Olivier Casasnovas, Anne Donzel, Laurence Jego, Bernard Aral, Julien Guy, Nathalie Nadal, Dewi Vernerey, Patrick Callier, Francine Garnache-Ottou and Christophe Ferrand

    Citation: Experimental Hematology & Oncology 2018 7:5

    Published on:

  4. Content type: Case report

    Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor and immunomodulatory mechanisms of action, demonstrated clinical benefit as monotherapy or in combination with established regimens in pat...

    Authors: Saad Z. Usmani, Imran Khan, Christopher Chiu, David Foureau, Lawrence J. Druhan, Katherine Rigby, Tineke Casneuf and A. Kate Sasser

    Citation: Experimental Hematology & Oncology 2018 7:3

    Published on:

  5. Content type: Case report

    Currently, there are no data available on the best choice of treatment in heavily pretreated patients with advanced breast cancer. However, the combination of oral vinorelbine and capecitabine has been demonst...

    Authors: V. Sgroi, M. Bassanelli, M. Roberto, E. Iannicelli, R. Porrini, P. Pellegrini, A. Tafuri and P. Marchetti

    Citation: Experimental Hematology & Oncology 2018 7:2

    Published on:

  6. Content type: Research

    The optimal strategy for vaccination to induce CD8+ T cell responses against WT1 is not known.

    Authors: Hongtao Liu, Yuanyuan Zha, Noura Choudhury, Gregory Malnassy, Noreen Fulton, Margaret Green, Jae-Hyun Park, Yusuke Nakamura, Richard A. Larson, Andres M. Salazar, Olatoyosi Odenike, Thomas F. Gajewski and Wendy Stock

    Citation: Experimental Hematology & Oncology 2018 7:1

    Published on:

  7. Content type: Case report

    Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreact...

    Authors: Mauricio Sarmiento Maldonado, Pablo Ramírez Villanueva, Pablo Bertín Cortes-Monroy, Veronica Jara Arias, Katherine Soto Donoso, Pablo Uribe Gonzalez, Mauricio Ocqueteau Tachini and Jose Antonio Perez-Simón

    Citation: Experimental Hematology & Oncology 2017 6:32

    Published on:

  8. Content type: Review

    HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HE...

    Authors: Shengnan Yu, Qian Liu, Xinwei Han, Shuang Qin, Weiheng Zhao, Anping Li and Kongming Wu

    Citation: Experimental Hematology & Oncology 2017 6:31

    Published on:

  9. Content type: Research

    Pegylated interferon alfa-2a (PEG-IFN-α-2a) is a potent immunomodulating agent capable of inducing high rate of hematologic and even complete molecular remission in patients with essential thrombocythemia (ET)...

    Authors: Lucia Masarova, C. Cameron Yin, Jorge E. Cortes, Marina Konopleva, Gautam Borthakur, Kate J. Newberry, Hagop M. Kantarjian, Carlos E. Bueso-Ramos and Srdan Verstovsek

    Citation: Experimental Hematology & Oncology 2017 6:30

    Published on:

  10. Content type: Case report

    The treatment algorithm for metastatic non-small cell lung cancers (NSCLCs) has been evolving rapidly due to the development of new therapeutic agents. Although guidelines are provided by National Comprehensiv...

    Authors: Shuyu D. Li, Annia Martial, Alexa B. Schrock and Jane J. Liu

    Citation: Experimental Hematology & Oncology 2017 6:29

    Published on:

  11. Content type: Research

    Carfilzomib is approved in the United States and Europe for treatment of relapsed or refractory multiple myeloma (MM). This study evaluated pharmacokinetics (PK) and safety of carfilzomib in patients with rela...

    Authors: Jennifer Brown, Ruth Plummer, Todd M. Bauer, Stephen Anthony, John Sarantopoulos, Filip De Vos, Mike White, Marco Schupp, Ying Ou and Ulka Vaishampayan

    Citation: Experimental Hematology & Oncology 2017 6:27

    Published on:

  12. Content type: Research

    Post-transplant lymphoproliferative disorder is a well-recognized but rare complication of hematopoietic stem cell and solid organ transplant. Due to rarity of this disease, retrospective studies from major tr...

    Authors: Rohit Bishnoi, Ravneet Bajwa, Aaron J. Franke, William Paul Skelton IV, Yu Wang, Niraj M. Patel, William Birdsall Slayton, Fei Zou and Nam H. Dang

    Citation: Experimental Hematology & Oncology 2017 6:26

    Published on:

  13. Content type: Review

    Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been considered as a valuable approach in treatment of numerous malignant and none malignant hematologic disorders. However, relapse and poor ...

    Authors: Saeed Mohammadi, Amir Hossein Norooznezhad, Ashraf Malek Mohammadi, Hajar Nasiri, Mohsen Nikbakht, Najmaldin Saki, Mohammad Vaezi, Kamran Alimoghaddam and Ardeshir Ghavamzadeh

    Citation: Experimental Hematology & Oncology 2017 6:24

    Published on:

  14. Content type: Short report

    Traditional two-dimensional (2-D) monolayer cell culture is vastly different from in vivo physiological conditions, which can lead to inaccurate or insufficient data in areas where response and efficacy within...

    Authors: Jiaojiao Zhou, Jimmy Su, Xiaotong Fu, Lei Zheng and Zhizhong Yin

    Citation: Experimental Hematology & Oncology 2017 6:22

    Published on:

  15. Content type: Review

    B cell lymphoma and multiple myeloma (MM) are the most common hematological malignancies which benefit from therapeutic monoclonal antibodies (mAbs)-based immunotherapies. Despite significant improvement on pa...

    Authors: Li Zhang, Yu-Tzu Tai, Matthew Zhi Guang Ho, Lugui Qiu and Kenneth C. Anderson

    Citation: Experimental Hematology & Oncology 2017 6:20

    Published on:

  16. Content type: Case report

    Heparin-induced thrombocytopenia (HIT) is a life and limb-threatening condition caused by the binding of platelet-activating antibodies (IgG) to multimolecular platelet factor 4 (PF4)/heparin complexes because...

    Authors: Daniel E. Ezekwudo, Rebecca Chacko, Bolanle Gbadamosi, Syeda Batool, Sussana Gaikazian, Theodore E. Warkentin, Jo-Ann I. Sheppard and Ishmael Jaiyesimi

    Citation: Experimental Hematology & Oncology 2017 6:21

    Published on:

  17. Content type: Research

    Inflammation is a major feature of sickle cell disease (SCD). Low-dose methotrexate (MTX) has long been used in chronic inflammatory diseases. This pilot study examined the MTX effect on acute vaso-occlusive p...

    Authors: Silvia R. Brandalise, Rosemary Assis, Angelo B. A. Laranjeira, José Andrés Yunes and Pedro O. de Campos-Lima

    Citation: Experimental Hematology & Oncology 2017 6:18

    Published on:

  18. Content type: Review

    Cullin 4B (CUL4B) is a scaffold of the Cullin4B-Ring E3 ligase complex (CRL4B) that plays an important role in proteolysis and is implicated in tumorigenesis. Aberrant expression of CUL4B has been reported in ...

    Authors: Ying Li and Xin Wang

    Citation: Experimental Hematology & Oncology 2017 6:17

    Published on:

  19. Content type: Research

    Multiple myeloma (MM) is a type of hematological malignancy with significant heterogeneity in clinical features and prognosis. Cytogenetic abnormalities are the major factors affecting patient outcomes. Studie...

    Authors: GuoQing Wei, LiJun Wang, HanJin Yang, XiaoYan Han, GaoFeng Zheng, WeiYan Zheng, Jie Sun, JiMin Shi, WenJun Wu, Yi Zhao, DongHua He, Bo Wang, Zhen Cai and JingSong He

    Citation: Experimental Hematology & Oncology 2017 6:16

    Published on:

Previous Page Page 1 of 9 Next Page

2016 Journal Metrics